Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

4.035 +0.125 (+3.20%)
Streaming Delayed Price Updated: 10:06 AM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bioxcel Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Expert Ratings for BioXcel Therapeutics
Via Benzinga
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. 
Via Benzinga
Why Is Dementia Focused BioXcel Therapeutics Stock Trading Lower Today?
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program of BXCL501 for acute treatment of agitation associated  
Via Benzinga
Recap: BioXcel Therapeutics Q3 Earnings
Via Benzinga
Earnings Outlook For BioXcel Therapeutics
Via Benzinga
Where BioXcel Therapeutics Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients wi 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% to 33,025.71 while the NASDAQ fell 2.45% to 12,817.76.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Expectations for BioXcel Therapeutics's Future
Via Benzinga
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Shell Layoffs 2023: What to Know About the Latest SHEL Job Cuts
Shell layoffs are on the horizon as the petrol company prepares to cut 200 jobs in 2024 with another 130 jobs under review. 
Via InvestorPlace
Topics Energy Workforce
Exposures Fossil Fuels Layoff
EVGO Stock Slips as TD Cowen Downgrades EVgo
EVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut. 
Via InvestorPlace
Nasdaq Down 1.5%; Microsoft Posts Upbeat Results
U.S. stocks traded lower this morning, with the Nasdaq Composite falling 1.5% on Wednesday. Following the market opening Wednesday, the Dow traded down 0.26% to 33,053.68 while the NASDAQ fell 1.50% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today?
BioXcel Therapeutics stock is rising on Wednesday as investors in BTAI stock react to results from an audit on a clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Schizophrenia Player BioXcel's Drug Faces Funding Headwinds, Analyst Downgrades Stock
Truist downgraded BioXcel Therapeutics Inc (NASDAQ: BTAI) from Buy to Hold, citing significant near-term funding and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
Why Shares of BioXcel Therapeutics Fell This Week
The company's co-founder is leaving, and layoffs are coming. 
Via The Motley Fool
Topics Workforce
Exposures Layoff
Why BioXcel Therapeutics Stock Flopped Again Today
Major changes are afoot with the company, and few are happy about them. 
Via The Motley Fool
Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy
Mizuho analyst Graig Suvannavejh downgraded BioXcel Therapeutics, Inc. (NASDAQ: BTAI) to Neutral from Buy,  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
NVIDIA To Rally More Than 23%? Here Are 10 Other Analyst Forecasts For Tuesday
B of A Securities lowered the price target for Valero Energy Corporation (NYSE: BMBL) from $160 to $152. B of A Securities analyst Doug Leggate downgraded the stock from Buy to Neutral. Valero Energy... 
Via Benzinga
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
3 Biotech Stocks to Sell in August Before They Crash and Burn
These biotech stocks are set to crash and burn, so it's probably a good idea for investors to sell in August, before it's too late. 
Via InvestorPlace
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
US Stocks Turn Higher; BioXcel Therapeutics Shares Plummet
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 80 points on Monday. The Dow traded up 0.01% to 35,284.34 while the NASDAQ rose 0.64% to 13,732.05.... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.